TY - JOUR
T1 - Number needed to treat for net effect of anticoagulation in atrial fibrillation
T2 - Real-World vs. Clinical Trial Evidence
AU - Ding, Wern Yew
AU - Rivera-Caravaca, José Miguel
AU - Marín, Francisco
AU - Li, Guowei
AU - Roldán, Vanessa
AU - Lip, Gregory Y H
N1 - © 2021 British Pharmacological Society.
PY - 2022/1
Y1 - 2022/1
N2 - Aims: The net benefit of oral anticoagulants (OACs) in atrial fibrillation (AF) is poorly understood. We aimed to determine the NNT for net effect (NNT
net) using calculator of absolute stroke risk (CARS) in anticoagulated patients with AF in real-world and clinical trial cohorts. Methods: Post-hoc analysis of patient-level data from the real-world Murcia AF Project and AMADEUS clinical trial. Baseline risk of stroke was determined using CARS. The risk of stroke and major bleeding events with OAC were determined using the number of respective events at 1-year. NNT
net was calculated as a reciprocal of the net effect of absolute risk reduction with OAC (NNT
net = 1/(absolute risk reduction of stroke[ARR
stroke] − absolute risk increase of major bleeding[ARI
bleeding])). Results: In total, 3511 patients were included (1306 [37.2%] real-world patients and 2205 [62.8%] clinical trial participants). The absolute 1-year stroke risk was similar across both cohorts. In the real-world cohort, OAC was associated with a 4.0% ARR
stroke, 25 NNT
benefit, 1.0% ARI
bleeding, 100 NNT
harm and 34 NNT
net. In the clinical trial cohort, OAC was associated with a 3.8% ARR
stroke, 27 NNT
benefit, 1.6% ARI
bleeding, 63 NNT
harm and 46 NNT
net. In both cohorts, the NNT
net was significantly lower in patients with an excess stroke risk of ≥2% by CARS. Conclusion: Overall, the NNT
net approach in AF incorporates information regarding baseline risk of stroke and major bleeding, and relative effects of OAC with the potential to include multiple additional outcomes and weighting of events based on their perceived effects by individual patients.
AB - Aims: The net benefit of oral anticoagulants (OACs) in atrial fibrillation (AF) is poorly understood. We aimed to determine the NNT for net effect (NNT
net) using calculator of absolute stroke risk (CARS) in anticoagulated patients with AF in real-world and clinical trial cohorts. Methods: Post-hoc analysis of patient-level data from the real-world Murcia AF Project and AMADEUS clinical trial. Baseline risk of stroke was determined using CARS. The risk of stroke and major bleeding events with OAC were determined using the number of respective events at 1-year. NNT
net was calculated as a reciprocal of the net effect of absolute risk reduction with OAC (NNT
net = 1/(absolute risk reduction of stroke[ARR
stroke] − absolute risk increase of major bleeding[ARI
bleeding])). Results: In total, 3511 patients were included (1306 [37.2%] real-world patients and 2205 [62.8%] clinical trial participants). The absolute 1-year stroke risk was similar across both cohorts. In the real-world cohort, OAC was associated with a 4.0% ARR
stroke, 25 NNT
benefit, 1.0% ARI
bleeding, 100 NNT
harm and 34 NNT
net. In the clinical trial cohort, OAC was associated with a 3.8% ARR
stroke, 27 NNT
benefit, 1.6% ARI
bleeding, 63 NNT
harm and 46 NNT
net. In both cohorts, the NNT
net was significantly lower in patients with an excess stroke risk of ≥2% by CARS. Conclusion: Overall, the NNT
net approach in AF incorporates information regarding baseline risk of stroke and major bleeding, and relative effects of OAC with the potential to include multiple additional outcomes and weighting of events based on their perceived effects by individual patients.
KW - atrial fibrillation, benefit, harm, number needed to treat, number needed to treat for net effect
UR - http://www.scopus.com/inward/record.url?scp=85109900282&partnerID=8YFLogxK
U2 - 10.1111/bcp.14961
DO - 10.1111/bcp.14961
M3 - Journal article
C2 - 34192808
SN - 0306-5251
VL - 88
SP - 282
EP - 289
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
IS - 1
ER -